Hexagon Bio
Home - Hexagon
Menlo Park, United States · Founded 2017 · $185.3M raised
- Headquarters
- Menlo Park, California
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- hexagonbio.com
- Total Funding
- $185.3M
- Last Round
- $77.3M Series CFeb 2023
- Rounds
- 3
About
Hexagon Bio is a biopharmaceutical company developing novel antibody-drug conjugate (ADC) payloads for oncology. Its proprietary natural products platform mines cytotoxic small molecules from microbial genomes using data science, genomics, synthetic biology, and automation to identify next-generation ADC payloads that overcome resistance to existing therapies and expand indication space.
Summary
Hexagon Bio is a Biotech company based in Menlo Park, United States, founded in 2017. It has raised $185.3M in total across 3 rounds, most recently a $77.3M Series C round in Feb 2023.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Uses AI to analyze natural chemistry and accelerate discovery of new medicines for biopharma and ...
Biopharmaceutical company pioneering Helicon peptide drugs to target previously undruggable prote...